Item 2.02 Results of Operations and Financial Condition.

On April 1, 2020, Nevro Corp. ("Nevro" or the "Company") issued a press release relating to its preliminary unaudited financial results for the three months ended March 31, 2020, the Company's suspension of its previously announced annual guidance for 2020 in light of the continued uncertainties resulting from the impact of COVID-19 and actions the Company has taken in response to COVID-19. The full text of the press release is furnished herewith as Exhibit 99.1.

The information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.




 Exhibit
   No.           Description

   99.1            Press release dated April 1, 2020.

   104           Cover Page Interactive Data File (embedded within the Inline XBRL
                 document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses